Pfizer inks collaboration deal to use CytoReason's cell-centered models of immune system

Microsoft has revamped its MMLSpark open source project (Image kamisoka / iStockPhoto)
CytoReason expects to receive payments from Pfizer that could reach into “low double-digit millions” of U.S. dollars. (kamisoka/iStockPhoto)

Pharma giant Pfizer has inked a deal with CytoReason to use the Tel Aviv-based drug discovery and development company’s cell-centered models of the immune system.

CytoReason’s machine learning technology can rebuild lost cellular information from gene expression data and associate genes to specific cells. In turn, that information is integrated with other data to create a cell-based model of the trial-specific immune response.

Although financial terms of the deal weren’t disclosed, CytoReason expects to receive payments from Pfizer that could reach into “low double-digit millions” of U.S. dollars.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“This will be our fifth major partnership, which we believe will help make our model unparalleled in its accuracy for assets across the pipeline,” David Harel, CytoReason’s chief executive, said in a statement (PDF). “CytoReason’s model brings together thousands of samples on a cell-protein-gene level, allowing for fast and accurate insights.”

So far, the company has two pending patents, 10 commercial and scientific collaborations and 16 peer-reviewed publications. Its technology can target cancer immunotherapy, autoimmune, neurodegenerative and infectious diseases.

Suggested Articles

Qiagen is collaborating with Ares Genetics to develop new bioinformatics and assay solutions for research targeting antibiotic-resistant bacteria.

STA Pharmaceutical has signed an exclusive technology and marketing deal with Swiss biotech BioLingus.

Clinerion is partnering with Citeline to give clinical researchers a more comprehensive approach to making evidence-based decisions.